Curtailed two-stage design for comparing two arms in randomized phase II clinical trials

• Published in: Journal of biopharmaceutical statistics 2018-09, Vol.28 (5), p.939-950
• Main Authors: Chen, Chia-Min, Chi, Yunchan, Chang, Hsing-Ming
• Format: Article
• Language: English
• Subjects: Clinical trials; Curtailed two-stage design; design parameters; Drug development; expected sample size
• ISSN: 1054-3406; 1520-5711
• DOI: 10.1080/10543406.2018.1428615

In phase II clinical trials, patients are recruited sequentially and consequently the time required to complete the clinical trial will become long if the accrual rate is low. To speed up the drug development process and account for ethical issues, stochastically and non-stochastically curtailed two-stage designs have been proposed in single-arm phase II clinical trials. More recently, randomized phase II clinical trials are being increasingly recommended to avoid biased evaluation of the treatment effect when compared with a historical control. The current patient population and the historical one may be quite heterogeneous. Moreover, it is impossible to randomly assign patients for treatments. Consequently, various two-stage designs have been presented for comparing two arms. Since the sample size required in a randomized phase II trial is usually larger than that required in a single-arm phase II trial, we introduce the concept of curtailed sampling procedure to develop curtailed two-stage design for two-armed, randomized phase II clinical trials. The proposed design does not require pairwise patient response comparison, yet it allows a trial to be stopped early as soon as the difference in therapeutic effect of the experimental therapy and the standard at the end of a trial is foreknown. Copyright © 2017 Taylor & Francis Group, LLC